GlassScriptPhysician profile
Gregory G Bojrab
NPI 1922090182
$12,292.89
in general payments reported to CMS, 2019-2025
36 companies · $1,871 in 2025
The $1,871 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,287 · 2020: $982 · 2021: $1,475 · 2022: $2,078 · 2023: $2,109 · 2024: $1,491 · 2025: $1,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,433 · Education: $37.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,433.28 |
| Education | $37.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,478.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,389.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $995.12 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $933.74 | 2019-2024 | Camzyos, Eliquis |
| Glaxosmithkline, LLC. | $741.29 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $720.28 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $558.39 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $368.83 | 2020-2023 | Uzedy |
| Biohaven Pharmaceuticals, INC. | $359.00 | 2021 | |
| Amgen INC. | $316.31 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $265.19 | 2022 | |
| Allergan, INC. | $240.42 | 2019-2020 | |
| Medtronic, INC. | $234.33 | 2022-2025 | Intellis Adaptivestim, Signia |
| Pfizer INC. | $231.61 | 2019-2025 | |
| Exact Sciences Corporation | $174.00 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $166.50 | 2024 | Amvuttra, Onpattro |
| Janssen Pharmaceuticals, INC | $138.23 | 2019-2021 | |
| Amarin Pharma, INC. | $120.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.62 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $110.43 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $108.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $77.26 | 2019-2024 | |
| Lundbeck LLC | $62.25 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $59.76 | 2022-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.74 | 2023-2025 | Jardiance |
| Corium, LLC | $44.65 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $43.07 | 2023-2024 | Rexulti |
| Biogen, INC. | $35.10 | 2025 | Zurzuvae |
| Jazz Pharmaceuticals INC. | $29.31 | 2022-2023 | Xywav |
| Vanda Pharmaceuticals INC. | $28.35 | 2022 | |
| Sumitomo Pharma America, INC. | $21.22 | 2025 | Gemtesa |
| Collegium Pharmaceutical, INC. | $19.94 | 2025 | Jornay Pm |
| Axonics, INC. | $14.94 | 2022 | |
| Astellas Pharma US INC | $14.55 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $13.36 | 2019 | |
| Covis Pharma Gmbh | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Bojrab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.